摘要
目的探讨齐拉西酮与利培酮治疗女性少年儿童精神分裂症患者的临床疗效及安全性。方法将60例女性少年儿童精神分裂症患者随机分为两组，每组30例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察8周。于治疗前及治疗第2周、4周、6周、8周末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗2周末起，两组阳性与阴性症状量表总分及各因子分均较治疗前有显著性下降（P〈0.05或0．01），同期两组评分比较差异均无显著性（P〉0．05）；治疗8周末，研究组显效率63．3％、总有效率83．3％，对照组分别为70．0％、86．7％，两组比较差异无显著性（χ^2=0．30、0．13，P〉0.05）。研究组不良反应发生率为40．0％，对照组为46．7％，两组比较差异无显著性（χ^2=0．27，P〉0.05），但研究组体质量增加、闭经、溢乳发生率显著低于对照组（P〈0.01）。结论齐拉西酮与利培酮治疗女性少年儿童精神分裂症疗效显著且相当，安全性高，但齐拉西酮对体质量及内分泌影响较小，更适用处于生长发育期的女性少年儿童精神分裂症患者。
Objective To explore the efficacy and safety of ziprasidone vs. risperidone in the treatment of female child and adolescent schizophrenia. Methods Sixty female child and adolescent schizophrenics were randomly assigned to two groups of 30 patients each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） at baseline and at the end of the 2^nd , 4^th, 6^th and 8^th week and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results Since the end of the 2nd week the total and each factor scores of both groups lowered more significantly compared with pretreatment （P〈0.05 or 0. 01）, but those had group differences （P〉0. 05） ; at the end of the 8^th week, obvious and total effective rate was respectively 63.3% and 83.3% in research and 70.0% and 86.7% in control group, which showed no significant differences （χ^2 =0.30, 0.13,P〉0. 05）. Incidences of adverse reactions were respectively 40.0% in research and 46.7% in control group and showed no significant difference （χ^2 =0.27,P〉0.05）, but those of increased body weight, amenorrhea and galactorrhea were significantly lower in the former than in the latter （P〈0.01）. Conclusion Both ziprasidone and risperidone have an equivalent and evident effect and higher safety in the treatment of female child and adolescent schizophrenia, but the former has less effect on body mass and endocrine and is more suitable for female child and adolescent schizophrenics in the growth development period.
出处
《临床心身疾病杂志》
CAS
2013年第2期124-126,共3页
Journal of Clinical Psychosomatic Diseases
作者简介
栗永刚，男，36岁，汉族，大专，主治医师，科主任。研究方向：抗精神病药物对内分泌代谢的影响。
